A Phase 3 interventional study of phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist and Placebo in Mesopic Vision and Night Vision Loss, sponsored by Opus Genetics, Inc. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Opus Genetics, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Vitamin A Deficiency with a site in United States — 5 open to participants now, 6 under way, 1 of them phase 3. Vitamin A Deficiency · United States.
Among the 16 studies in Vitamin A Deficiency with a site in United States, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 3, and was the 12th registered.
67 studies on the registry are indexed under Vitamin A Deficiency; 7 are open to participants now.
Browse Vitamin A Deficiency studies →5 of the 16 studies in Vitamin A Deficiency with a site in United States are open now. Recruiting first, the newest first:
Opus Genetics, Inc · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 18–60 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 18+
MD Stem Cells · Sites in United States, Austria, United Arab Emirates
Ages 18+
University of Mississippi Medical Center · Sites in United States
Ages 18–45
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Vitamin A Deficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is close to the median of 200 across 49 interventional studies indexed under Vitamin A Deficiency.
Median enrollment 86 across the 12 interventional studies, 48 across the 4 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 16 have an industry lead sponsor. The 10 most frequent:
Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Opus Genetics, Inc has 2 studies filed under Vitamin A Deficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Vitamin A Deficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140783Phase 3Opus Genetics, IncOPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity | 2027-08 |
| NCT07736768University of Mississippi Medical CenterVitamin A Supplementation and Breast Milk Vitamin A Levels in Mothers of Preterm Infants | 2027-07-30 |
| NCT03011541MD Stem CellsStem Cell Ophthalmology Treatment Study II | 2027-07-31 |
| NCT06450925Children's Hospital Medical Center, CincinnatiVitamin A Supplementation in Allogeneic Stem Cell Transplantation. | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies in Vitamin A Deficiency with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.
Randomized, placebo-controlled, double-masked study of the safety and efficacy of POS (0.75% Phentolamine Ophthalmic Solution) in subjects who have previously had keratorefractive surgery and have decreased visual acuity (VA) under mesopic conditions
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Able to self-administer study medication
Inclusion criteria #6, #7, and #8 must all be met in the same eye:
Exclusion Criteria:
Ophthalmic (in either eye):
Previously undiagnosed dry eye, at the determination of the Investigator. Dry eye diagnosis should be based on one of the following dry eye test results: tear break-up time \< 5 seconds, or corneal fluorescein staining ≥ Grade 2 in the inferior zone or ≥ Grade 1 in the central zone using the National Eye Institute scale
Systemic:
Known hypersensitivity or contraindication to alpha- and/or beta-adrenoceptor antagonists (eg, or bronchial asthma; abnormally low BP or HR; second- or third-degree heart blockage or congestive heart failure; or severe diabetes as defined below)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily dosing
Drug: phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
Daily dosing
Drug: Placebo
Drug page: Phentolamine
Once daily dosing
Also known as: Nyxol
Once daily dosing
Also known as: phentolamine ophthalmic solution vehicle
Percentage of Subjects With ≥ 15 Letters (3 Lines) Improvement in mLCVA in the Study Eye at Day 15 Compared to Baseline
This outcome measure will investigate the percent of subjects with an increase of at least 15 ETDRS letters read (≥ 3 lines) in the study eye in mLCVA compared to baseline (Day 1 pre-dose) at Day 15 in an effort to evaluate the efficacy of POS to improve mLCVA in subjects with post-refractive surgery visual disturbances.
Time frame: 15 Days
Percentage of Subjects With ≥ 10 and ≥ 15 ETDRS Letters Improvement in mLCVA Compared to Baseline (Day 1 Pre-dose) at Days 3, 8, and 15 (≥ 10 ETDRS Letters Only) and Week 6
This outcome measure will investigate the percentage of subjects with ≥ 10 and ≥ 15 ETDRS letters improvement in mLCVA compared to baseline at Days 3, 8, and 15 (≥ 10 ETDRS letters only) and Week 6.
Time frame: 6 Weeks
Mean and Change From Baseline in mLCVA at 0.5, 1, and 3 Hours Post-dose on Day 1
This outcome measure will investigate the mean and change from baseline in mLCVA at 0.5, 1, and 3 hours post-dose on Day 1.
Time frame: 3 hours
Percentage of Subjects With ≥ 10 and ≥ 15 ETDRS Letters Improvement in Mesopic High-contrast Best-corrected Distance Visual Acuity (mHCVA) Compared to Baseline (Day 1 Pre-Dose) at Days 3, 8, and 15 and Week 6
This outcome measure will investigate the percentage of subjects with ≥ 10 and ≥ 15 ETDRS letters improvement in mesopic high-contrast best-corrected distance visual acuity (mHCVA) compared to baseline at Days 3, 8, and 15 and Week 6.
Time frame: 6 Weeks
Mean and Change From Baseline (Day 1 Pre-dose) in mLCVA and mHCVA at Days 3, 8, and 15 and Week 6
This outcome measure will investigate the mean and change from baseline in mLCVA and mHCVA at Days 3, 8, and 15 and Week 6.
Time frame: 6 Weeks
Mean and Change From Baseline (Day 1 Pre-dose) in PD at Days 3, 8, and 15 and Week 6
This outcome measure will investigate the mean and change from baseline in PD at Days 3, 8, and 15 and Week 6.
Time frame: 6 Weeks
Change in Subject Questionnaire Responses Compared to Baseline (Day 1 Pre-dose) at Days 3, 8, and 15 and Week 6
This outcome measure will investigate the change in subject questionnaire responses compared to baseline at Days 3, 8, and 15 and Week 6. The Vision and Night Driving Questionnaire (VND-Q) is comprised of 9 questions related to visual difficulties when driving at night. Subjects were asked to assess, on a 1 (no difficulty) to 5 (extreme difficulty) scale, how much difficulty they had or would have with certain tasks while wearing their normal glasses or contact lenses (if any) for night driving.
Time frame: 6 Weeks
| Milestone | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Started | 100 | 100 |
| Completed | 78 | 87 |
| Not completed | 22 | 13 |
This outcome measure will investigate the percent of subjects with an increase of at least 15 ETDRS letters read (≥ 3 lines) in the study eye in mLCVA compared to baseline (Day 1 pre-dose) at Day 15 in an effort to evaluate the efficacy of POS to improve mLCVA in subjects with post-refractive surgery visual disturbances.
| Participants | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Percentage of Subjects With ≥ 15 Letters (3 Lines) Improvement in mLCVA in the Study Eye at Day 15 Compared to Baseline | 17 | 9 |
This outcome measure will investigate the percentage of subjects with ≥ 10 and ≥ 15 ETDRS letters improvement in mLCVA compared to baseline at Days 3, 8, and 15 (≥ 10 ETDRS letters only) and Week 6.
| Participants | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Day 3: >= 15 Letters (>= 3 Lines) | 17 | 12 |
| Day 3: >= 10 Letters (>= 2 Lines) | 57 | 38 |
| Day 8: >= 15 Letters (>= 3 Lines) | 16 | 8 |
| Day 8: >= 10 Letters (>= 2 Lines) | 59 | 35 |
| Day 15: >= 15 Letters (>= 3 Lines) | 17 | 9 |
| Day 15: >= 10 Letters (>= 2 Lines) | 51 | 42 |
| Week 6: >= 15 Letters (>= 3 Lines) | 16 | 14 |
| Week 6: >= 10 Letters (>= 2 Lines) | 42 | 38 |
This outcome measure will investigate the mean and change from baseline in mLCVA at 0.5, 1, and 3 hours post-dose on Day 1.
| Letters Read | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Day 1, 0.5 Hour Post-dose | 6.87 ± 0.571 | 5.76 ± 0.568 |
| Day 1, 1 Hour Post-dose | 9.70 ± 0.529 | 6.67 ± 0.526 |
| Day 1, 3 Hours Post-dose | 10.70 ± 0.554 | 6.65 ± 0.552 |
This outcome measure will investigate the percentage of subjects with ≥ 10 and ≥ 15 ETDRS letters improvement in mesopic high-contrast best-corrected distance visual acuity (mHCVA) compared to baseline at Days 3, 8, and 15 and Week 6.
| Participants | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Day 3: >= 15 Letters (>= 3 Lines) | 4 | 1 |
| Day 3: >= 10 Letters (>= 2 Lines) | 10 | 2 |
| Day 8: >= 15 Letters (>= 3 Lines) | 4 | 2 |
| Day 8: >= 10 Letters (>= 2 Lines) | 9 | 5 |
| Day 15: >= 15 Letters (>= 3 Lines) | 4 | 2 |
| Day 15: >= 10 Letters (>= 2 Lines) | 10 | 9 |
| Week 6: >= 15 Letters (>= 3 Lines) | 5 | 3 |
| Week 6: >= 10 Letters (>= 2 Lines) | 12 | 8 |
This outcome measure will investigate the mean and change from baseline in mLCVA and mHCVA at Days 3, 8, and 15 and Week 6.
| Letters Read | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Day 3, Change from Baseline in mHCVA | 3.00 ± 0.471 | 1.26 ± 0.467 |
| Day 8, Change from Baseline in mHCVA | 3.83 ± 0.508 | 1.32 ± 0.507 |
| Day 15, Change from Baseline in mHCVA | 4.13 ± 0.483 | 2.06 ± 0.481 |
| Week 6, Change from Baseline in mHCVA | 3.36 ± 0.517 | 2.24 ± 0.514 |
| Day 3, Change from Baseline in mLCVA | 10.66 ± 0.554 | 7.48 ± 0.551 |
| Day 8, Change from Baseline in mLCVA | 10.71 ± 0.545 | 6.86 ± 0.545 |
| Day 15, Change from Baseline in mLCVA | 10.01 ± 0.582 | 7.67 ± 0.582 |
| Week 6, Change from Baseline in mLCVA | 8.87 ± 0.629 | 8.05 ± 0.624 |
This outcome measure will investigate the mean and change from baseline in PD at Days 3, 8, and 15 and Week 6.
| millimeters | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Day 3 | -1.359 ± 0.0630 | -0.199 ± 0.0626 |
| Day 8 | -1.380 ± 0.0652 | -0.198 ± 0.0648 |
| Day 15 | -1.232 ± 0.0666 | -0.175 ± 0.0663 |
| Week 6 | -1.151 ± 0.0648 | -0.202 ± 0.0645 |
This outcome measure will investigate the change in subject questionnaire responses compared to baseline at Days 3, 8, and 15 and Week 6. The Vision and Night Driving Questionnaire (VND-Q) is comprised of 9 questions related to visual difficulties when driving at night. Subjects were asked to assess, on a 1 (no difficulty) to 5 (extreme difficulty) scale, how much difficulty they had or would have with certain tasks while wearing their normal glasses or contact lenses (if any) for night driving.
| Units on a Scale | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Day 3 | -0.24 ± 0.082 | -0.10 ± 0.082 |
| Day 8 | -0.61 ± 0.096 | -0.14 ± 0.096 |
| Day 15 | -0.97 ± 0.110 | -0.40 ± 0.110 |
| Week 6 | -1.34 ± 0.135 | -0.68 ± 0.134 |
Collected over from enrollment until end of study, up to 48 weeks. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.75% Phentolamine Ophthalmic Solution | 0/99 (0%) | 1/99 (1%) | 60/99 (60.6%) |
| Phentolamine Ophthalmic Solution Vehicle | 0/100 (0%) | 3/100 (3%) | 27/100 (27%) |
| Event | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/99 | 0/100 |
| Retinal detachmentEye disorders | 0/99 | 1/100 |
| Multiple fracturesInjury, poisoning and procedural complications | 0/99 | 1/100 |
| DehyrdrationMetabolism and nutrition disorders | 0/99 | 1/100 |
| Event | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Conjunctival hyperaemiaEye disorders | 35/99 | 5/100 |
| Instillation site irritationGeneral disorders | 19/99 | 1/100 |
| DysgeusiaNervous system disorders | 11/99 | 1/100 |
| Eczema eyelidsEye disorders | 5/99 | 0/100 |
| Instillation site erythemaGeneral disorders | 4/99 | 0/100 |
| Punctate keratitisEye disorders | 3/99 | 3/100 |
| Conjunctivitis allergicEye disorders | 3/99 | 0/100 |
| Foreign body sensation in eyesEye disorders | 0/99 | 3/100 |
| HypertensionVascular disorders | 1/99 | 3/100 |
| Vision blurredEye disorders | 2/99 | 1/100 |
200 patients in each arm started the study, however, one patient in the 0.75% POS group opted to not be dosed.
| Age, Continuous(Years) | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Mean | 45.3 ± 9.86 | 45.5 ± 10.92 | 45.4 ± 10.38 |
| Sex: Female, Male(Participants) | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Female | 69 | 35 | 104 |
| Male | 30 | 65 | 95 |
| Race (NIH/OMB)(Participants) | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 10 | 9 | 19 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 7 | 8 | 15 |
| White | 78 | 81 | 159 |
| More than one race | 2 | 2 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 9 | 22 |
| Not Hispanic or Latino | 86 | 91 | 177 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Study eye(Participants) | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Right eye | 49 | 45 | 94 |
| Left eye | 50 | 55 | 105 |
| Irides type(Participants) | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Light | 47 | 47 | 94 |
| Dark | 52 | 53 | 105 |
| Mesopic Low-Contrast Best-Corrected Distance Visual Acuity (mLCVA)(Letters Read) | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| in the Study Eye | 19.2 ± 6.00 | 17.8 ± 6.68 | 18.5 ± 6.37 |
| in the Fellow Eye | 22.7 ± 7.09 | 21.7 ± 6.67 | 22.2 ± 6.88 |
| Binocular | 28.0 ± 6.25 | 27.2 ± 5.82 | 27.6 ± 6.04 |
| Mesopic High-Contrast Best-Corrected Distance Visual Acuity (mHCVA)(Letters Read) | 0.75% Phentolamine Ophthalmic Solution | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| in the Study Eye | 49.5 ± 5.47 | 48.6 ± 6.31 | 49.0 ± 5.91 |
| in the Fellow Eye | 50.7 ± 5.81 | 49.6 ± 6.70 | 50.2 ± 6.28 |
| Binocular | 53.6 ± 4.70 | 52.4 ± 5.77 | 53.0 ± 5.29 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2024 to primary completion in Apr 2025, 12 months.
Results were first posted in Aug 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phentolamine
Opus Genetics, Inc